{
    "xml": "<topic id=\"PHP80933\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/epaxal\" basename=\"epaxal\" title=\"Epaxal\">\n<title>Epaxal<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP81338\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/clinical-medicinal-product-information/epaxal\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis A infection</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;17 years</p>\n<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 6&#8211;12&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 6&#8211;12&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Immunisation against hepatitis A infection (splenectomised patients)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;17 years</p>\n<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 1&#8211;6&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 1&#8211;6&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP100450\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.9\" parent=\"/clinical-medicinal-product-information/epaxal\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\n<sectiondiv>\n<p>\n<i>Epaxal</i>\n<tm tmtype=\"reg\"/> contains influenza virus haemagglutinin grown in the allantoic cavity of chick embryos, therefore contra-indicated in those hypersensitive to eggs or chicken protein.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP80933",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/epaxal",
    "basename": "epaxal",
    "title": "Epaxal",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis A infection",
                        "html": "Immunisation against hepatitis A infection"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "Initially 0.5 mL for 1 dose, then 0.5 mL after 6&#8211;12 months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 6&#8211;12&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>",
                        "ageGroup": "1&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 0.5 mL for 1 dose, then 0.5 mL after 6&#8211;12 months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 6&#8211;12&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Immunisation against hepatitis A infection (splenectomised patients)",
                        "html": "Immunisation against hepatitis A infection (splenectomised patients)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "Initially 0.5 mL for 1 dose, then 0.5 mL after 1&#8211;6 months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 1&#8211;6&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>",
                        "ageGroup": "1&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 0.5 mL for 1 dose, then 0.5 mL after 1&#8211;6 months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.",
                        "html": "<p>Initially 0.5&#8239;mL for 1 dose, then 0.5&#8239;mL after 1&#8211;6&#8239;months, dose given as booster; booster dose may be delayed by up to 4 years in adults if not given after recommended interval following primary dose. The deltoid region is the preferred site of injection. The subcutaneous route may be used for patients with bleeding disorders.</p>"
                    }
                ]
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "textContent": "Epaxal contains influenza virus haemagglutinin grown in the allantoic cavity of chick embryos, therefore contra-indicated in those hypersensitive to eggs or chicken protein.",
                "html": "<p>\n<i>Epaxal</i>\n<tm tmtype=\"reg\"/> contains influenza virus haemagglutinin grown in the allantoic cavity of chick embryos, therefore contra-indicated in those hypersensitive to eggs or chicken protein.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}